VKTX

Viking Therapeutics, Inc.

VKTX · CIK 1607678 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$0M
20182025
Net Income−$360M
20182025
Operating CF−$279M
20182025
Free Cash Flow
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue————————
Gross Profit————————
R&D Expense$0.3B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
SG&A Expense————————
Operating Income$-0.4B$-0.2B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
Net Income$-0.4B$-0.1B$-0.1B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-3.19$-1.01$-0.91$-0.90————
EPS (Diluted)$-3.19$-1.01$-0.91$-0.90————

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.7B$0.9B$0.4B$0.2B$0.2B$0.3B$0.3B$0.3B
Current Assets$0.7B$0.9B$0.4B$0.2B$0.2B$0.3B$0.3B$0.3B
Cash & Equivalents$0.2B$0.0B$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B
Total Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$0.6B$0.9B$0.3B$0.1B$0.2B$0.2B$0.3B$0.3B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.3B$-0.1B$-0.1B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.3B$-0.6B$-0.2B$0.1B$0.0B$0.0B$0.0B$-0.3B
Capital Expenditures————————
Financing Cash Flow$0.1B$0.6B$0.3B$0.0B$0.0B$0.0B$0.0B$0.3B
← Companies